TAPUR: Afprøvning af brugen af Food and Drug Administration (FDA) godkendte lægemidler, der retter sig mod en specifik abnormitet i et tumorgen hos mennesker med kræft i avanceret stadium (TAPUR)
Undersøgelse af målrettet agent og profileringsanvendelse Registry (TAPUR).
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug.
NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact TAPUR@asco.org, or if a patient, your nearest participating TAPUR site (see participating centers).
********************************************************************
Results in publication or poster presentation format are posted as they become available for individual cohorts at www.tapur.org/news. The results may be accessed at any time. All results will be made available on clinicaltrials.gov at the end of the study. Indexing of available results on PubMed is in progress.
********************************************************************
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
- Medicin: Sunitinib (CLOSED TO ENROLLMENT)
- Medicin: Trastuzumab and Pertuzumab (CLOSED TO ENROLLMENT)
- Medicin: Vemurafenib and Cobimetinib (CLOSED TO ENROLLMENT)
- Medicin: Olaparib (CLOSED TO ENROLLMENT)
- Medicin: Nivolumab and Ipilimumab (CLOSED TO ENROLLMENT)
- Medicin: Abemaciclib (CLOSED TO ENROLLMENT)
- Medicin: Talazoparib (CLOSED TO ENROLLMENT)
- Medicin: Atezolizumab and Talazoparib (CLOSED TO ENROLLMENT)
- Medicin: Tucatinib plus Trastuzumab Subcutaneous (SC) (CLOSED TO ENROLLMENT)
- Medicin: Futibatinib
- Medicin: Dabrafenib plus Trametinib
- Medicin: Fam-Trastuzumab Deruxtecan-Nxki (TDxD)
Detaljeret beskrivelse
The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a non-randomized clinical trial that aims to describe the safety and efficacy of commercially available, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic variant. TAPUR will study Food and Drug Administration (FDA)-approved targeted therapies that are contributed by collaborating pharmaceutical companies, catalogue the choice of molecular profiling test by clinical oncologists and develop hypotheses for additional clinical trials.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 2
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Laurie Smith, MA
- Telefonnummer: www.tapur.org
- E-mail: tapur@asco.org
Studiesteder
-
-
Alabama
-
Birmingham, Alabama, Forenede Stater, 35294
- Rekruttering
- University of Alabama at Birmingham Comprehensive Cancer Center
-
Ledende efterforsker:
- Mehmet Akce, MD
-
Kontakt:
- Kun Yuan
- Telefonnummer: 205-644-2584
- E-mail: kunyuan@uabmc.edu
-
-
Arizona
-
Phoenix, Arizona, Forenede Stater, 85338
- Rekruttering
- Cancer Treatment Centers of America-Phoenix
-
Ledende efterforsker:
- Sagun Shrestha, MD
-
Kontakt:
- Alex Lizzul
- Telefonnummer: 602-872-5654
- E-mail: alizzul@coh.org
-
-
California
-
Auburn, California, Forenede Stater, 95602
- Rekruttering
- Sutter Auburn
-
Kontakt:
- Kirsten Babski
- Telefonnummer: 916-878-4990
- E-mail: BabskiK@sutterhealth.org
-
Ledende efterforsker:
- Nitin Rohatgi, MD
-
Berkeley, California, Forenede Stater, 94705
- Rekruttering
- Sutter Alta Bates
-
Kontakt:
- Christopher Tang
- Telefonnummer: 510-204-3428
- E-mail: Christopher.Tang@sutterhealth.org
-
Ledende efterforsker:
- Nitin Rohatgi, MD
-
Los Angeles, California, Forenede Stater, 90025
- Rekruttering
- The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate
-
Kontakt:
- Teri Mata
- Telefonnummer: 310-231-2115
- E-mail: tmata@theangelesclinic.org
-
Ledende efterforsker:
- Omid Hamid, MD
-
Oakland, California, Forenede Stater, 94611
- Rekruttering
- Kaiser Permanente - Oakland Medical Center
-
Kontakt:
- Desiree Goldstein
- E-mail: desiree.goldstein@kp.org
-
Ledende efterforsker:
- Jennifer M Suga, MD
-
Palo Alto, California, Forenede Stater, 94301
- Rekruttering
- Sutter Palo Alto Medical Foundation: Palo Alto
-
Kontakt:
- E-mail: clinicaltrials@pamf.org
-
Roseville, California, Forenede Stater, 95661
- Rekruttering
- Kaiser Permanente - Roseville Medical Center
-
Kontakt:
- Desiree Goldstein
- E-mail: desiree.goldstein@kp.org
-
Ledende efterforsker:
- Jennifer M Suga, MD
-
Roseville, California, Forenede Stater, 95661
- Rekruttering
- Sutter Roseville
-
Kontakt:
- Kirsten Babski
- Telefonnummer: 916-878-4990
- E-mail: BabskiK@sutterhealth.org
-
Ledende efterforsker:
- Nitin Rohatgi, MD
-
Sacramento, California, Forenede Stater, 95814
- Rekruttering
- Kaiser Permanente - Sacramento Medical Center
-
Kontakt:
- Desiree Goldstein
- E-mail: desiree.goldstein@kp.org
-
Ledende efterforsker:
- Jennifer M Suga, MD
-
Sacramento, California, Forenede Stater, 95816
- Rekruttering
- Sutter Sacramento
-
Kontakt:
- E-mail: SIMR@sutterhealth.org
-
Ledende efterforsker:
- Nitin Rohatgi, MD
-
San Francisco, California, Forenede Stater, 94115
- Rekruttering
- California Pacific Medical Center Research Institute
-
Kontakt:
- Telefonnummer: 415-600-1654
- E-mail: clinicalresearch@sutterhealth.org
-
Ledende efterforsker:
- Nitin Rohatgi, MD
-
San Francisco, California, Forenede Stater, 94080
- Rekruttering
- Kaiser Permanente - South San Francisco Medical Center
-
Kontakt:
- Desiree Goldstein
- E-mail: desiree.goldstein@kp.org
-
Ledende efterforsker:
- Jennifer M Suga, MD
-
San Francisco, California, Forenede Stater, 94115
- Rekruttering
- Kaiser Permanente - San Francisco Medical Center
-
Kontakt:
- Desiree Goldstein
- E-mail: desiree.goldstein@kp.org
-
Ledende efterforsker:
- Jennifer M Suga, MD
-
San Francisco, California, Forenede Stater, 94115
- Rekruttering
- Sutter Cancer Research Consortium
-
Kontakt:
- Laurel Brechtel
- Telefonnummer: 415-600-1654
- E-mail: BrechtLa@cpmcri.org
-
Ledende efterforsker:
- Stacy D'Andre, MD
-
San Jose, California, Forenede Stater, 95119
- Rekruttering
- Kaiser Permanente - San Jose Medical Center
-
Kontakt:
- Desiree Goldstein
- E-mail: desiree.goldstein@kp.org
-
Ledende efterforsker:
- Jennifer M Suga, MD
-
San Leandro, California, Forenede Stater, 94577
- Rekruttering
- Kaiser Permanente - San Leandro Medical Center
-
Kontakt:
- Desiree Goldstein
- E-mail: desiree.goldstein@kp.org
-
Ledende efterforsker:
- Jennifer M Suga, MD
-
Santa Barbara, California, Forenede Stater, 93105
- Rekruttering
- Sutter Sansum Clinic
-
Ledende efterforsker:
- Nitin Rohatgi, MD
-
Kontakt:
- Selina Perez
- Telefonnummer: 831-458-5837
- E-mail: Selina.Perez@sutterhealth.org
-
Santa Clara, California, Forenede Stater, 95051
- Rekruttering
- Kaiser Permanente - Santa Clara Medical Center
-
Kontakt:
- Desiree Goldstein
- E-mail: desiree.goldstein@kp.org
-
Ledende efterforsker:
- Jennifer M Suga, MD
-
Santa Cruz, California, Forenede Stater, 95065
- Rekruttering
- Sutter Palo Alto Medical Foundation: Santa Cruz
-
Kontakt:
- E-mail: clinicaltrials@pamf.org
-
Santa Cruz, California, Forenede Stater, 994538
- Rekruttering
- Sutter Palo Alto Medical Foundation: Fremont
-
Kontakt:
- E-mail: clinicaltrials@pamf.org
-
Sunnyvale, California, Forenede Stater, 94086
- Rekruttering
- Sutter Palo Alto Medical Foundation: Sunnyvale
-
Kontakt:
- E-mail: clinicaltrials@pamf.org
-
Vallejo, California, Forenede Stater, 94589
- Rekruttering
- Kaiser Permanente - Vallejo Medical Center
-
Kontakt:
- Desiree Goldstein
- E-mail: desiree.goldstein@kp.org
-
Ledende efterforsker:
- Jennifer M. Suga, MD
-
Walnut Creek, California, Forenede Stater, 94596
- Rekruttering
- Kaiser Permanente - Walnut Creek Medical Center
-
Kontakt:
- Desiree Goldstein
- E-mail: desiree.goldstein@kp.org
-
Ledende efterforsker:
- Jennifer M Suga, MD
-
-
Connecticut
-
Bridgeport, Connecticut, Forenede Stater, 06606
- Rekruttering
- Saint Vincent's Medical Center (SVMC)
-
Kontakt:
- Telefonnummer: 860-972-4700
- E-mail: CancerResearchSupport@hhchealth.org
-
Ledende efterforsker:
- Wylie Hosmer, MD
-
Hartford, Connecticut, Forenede Stater, 06102
- Rekruttering
- Hartford Hospital
-
Kontakt:
- Telefonnummer: 860-972-4700
- E-mail: CancerResearchSupport@hhchealth.org
-
Ledende efterforsker:
- Wylie Hosmer, MD
-
Meriden, Connecticut, Forenede Stater, 06451
- Rekruttering
- Midstate Medical Center (MSMC)
-
Kontakt:
- Telefonnummer: 860-972-4700
- E-mail: CancerResearchSupport@hhchealth.org
-
Ledende efterforsker:
- Wylie Hosmer, MD
-
New Britain, Connecticut, Forenede Stater, 06053
- Rekruttering
- The Hospital of Central Connecticut (HOCC) Cancer Center
-
Ledende efterforsker:
- Wylie Hosmer, MD
-
Kontakt:
- Telefonnummer: 8609724700
- E-mail: CancerResearchSupport@hhchealth.org
-
Norwich, Connecticut, Forenede Stater, 06360
- Rekruttering
- William W. Backus Hospital
-
Kontakt:
- Telefonnummer: 860-972-4700
- E-mail: CancerResearchSupport@hhchealth.org
-
Ledende efterforsker:
- Wylie Hosmer, MD
-
Torrington, Connecticut, Forenede Stater, 06790
- Rekruttering
- Charlotte Hungerford
-
Kontakt:
- Telefonnummer: 860-972-4700
- E-mail: CancerResearchSupport@hhchealth.org
-
Ledende efterforsker:
- Wylie Hosmer, MD
-
Willimantic, Connecticut, Forenede Stater, 06226
- Rekruttering
- Windham Hospital (WH)
-
Kontakt:
- Telefonnummer: 860-972-4700
- E-mail: CancerResearchSupport@hhchealth.org
-
Ledende efterforsker:
- Wylie Hosmer, MD
-
-
Florida
-
Altamonte Springs, Florida, Forenede Stater, 32701
- Aktiv, ikke rekrutterende
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Aventura, Florida, Forenede Stater, 33180
- Rekruttering
- University of Miami/Sylvester Cancer Institute - Aventura
-
Kontakt:
- Carolina Troche, BS
- Telefonnummer: 305-243-1481
- E-mail: cxt582@med.miami.edu
-
Ledende efterforsker:
- Carmen Calfa, MD
-
Bonita Springs, Florida, Forenede Stater, 34135
- Aktiv, ikke rekrutterende
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Bradenton, Florida, Forenede Stater, 34211
- Aktiv, ikke rekrutterende
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Brandon, Florida, Forenede Stater, 33511
- Aktiv, ikke rekrutterende
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Cape Coral, Florida, Forenede Stater, 33909
- Aktiv, ikke rekrutterende
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Clearwater, Florida, Forenede Stater, 33761
- Aktiv, ikke rekrutterende
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Coral Gables, Florida, Forenede Stater, 33146
- Rekruttering
- University of Miami/Sylvester Cancer Institute - Lennar
-
Kontakt:
- Carolina Troche, BS
- Telefonnummer: 305-243-1481
- E-mail: cxt582@med.miami.edu
-
Ledende efterforsker:
- Carmen Calfa, MD
-
Deerfield Beach, Florida, Forenede Stater, 33442
- Rekruttering
- University of Miami/Sylvester Cancer Institute - Deerfield Beach
-
Kontakt:
- Carolina Troche, BS
- Telefonnummer: 305-243-1481
- E-mail: cxt582@med.miami.edu
-
Ledende efterforsker:
- Carmen Calfa, MD
-
Fort Lauderdale, Florida, Forenede Stater, 33308
- Rekruttering
- Holy Cross Hospital
-
Ledende efterforsker:
- Zdenka Segota, MD
-
Kontakt:
- Telefonnummer: 7347123671
- E-mail: MCRCwebsitecontactform@trinity-health.org
-
Fort Myers, Florida, Forenede Stater, 33901
- Aktiv, ikke rekrutterende
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Fort Myers, Florida, Forenede Stater, 33905
- Aktiv, ikke rekrutterende
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Fort Myers, Florida, Forenede Stater, 33908
- Aktiv, ikke rekrutterende
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Gainesville, Florida, Forenede Stater, 32610
- Rekruttering
- University of Florida Health
-
Ledende efterforsker:
- Thomas George, MD
-
Kontakt:
- Anna Kukulka, RN, BSN
- Telefonnummer: 352-293-2551
- E-mail: akukulka@ufl.edu
-
Gainesville, Florida, Forenede Stater, 32605
- Aktiv, ikke rekrutterende
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Largo, Florida, Forenede Stater, 33770
- Aktiv, ikke rekrutterende
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Lecanto, Florida, Forenede Stater, 34461
- Aktiv, ikke rekrutterende
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Miami, Florida, Forenede Stater, 33136
- Rekruttering
- University of Miami Sylvester Comprehensive Cancer Center
-
Kontakt:
- Carolina Troche, BS
- Telefonnummer: 305-243-1481
- E-mail: cxt582@med.miami.edu
-
Ledende efterforsker:
- Carmen Calfa, MD
-
Miami, Florida, Forenede Stater, 33136
- Rekruttering
- University of Miami/Sylvester Cancer Institute - Alex's Place
-
Kontakt:
- Carolina Troche, BS
- Telefonnummer: 305-243-1481
- E-mail: cxt582@med.miami.edu
-
Ledende efterforsker:
- Carmen Calfa, MD
-
Miami, Florida, Forenede Stater, 33136
- Rekruttering
- University of Miami/Sylvester Cancer Institute - Griffin Cancer Research Building
-
Kontakt:
- Carolina Troche, BS
- Telefonnummer: 305-243-1481
- E-mail: cxt582@med.miami.edu
-
Ledende efterforsker:
- Carmen Calfa, MD
-
Miami, Florida, Forenede Stater, 33176
- Rekruttering
- University of Miami/Sylvester Cancer Institute - Kendall
-
Kontakt:
- Carolina Troche, BS
- Telefonnummer: 305-243-1481
- E-mail: cxt582@med.miami.edu
-
Ledende efterforsker:
- Carmen Calfa, MD
-
Miami, Florida, Forenede Stater, 33181
- Rekruttering
- University of Miami/Sylvester Cancer Institute - Sole Mia
-
Kontakt:
- Carolina Troche, BS
- Telefonnummer: 305-243-1481
- E-mail: cxt582@med.miami.edu
-
Ledende efterforsker:
- Carmen Calfa, MD
-
Naples, Florida, Forenede Stater, 34102
- Aktiv, ikke rekrutterende
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Ocala, Florida, Forenede Stater, 34474
- Aktiv, ikke rekrutterende
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Orange City, Florida, Forenede Stater, 32763
- Aktiv, ikke rekrutterende
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Orlando, Florida, Forenede Stater, 32806
- Aktiv, ikke rekrutterende
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Plantation, Florida, Forenede Stater, 33324
- Rekruttering
- University of Miami/Sylvester Cancer Institute - Plantation
-
Kontakt:
- Carolina Troche, BS
- Telefonnummer: 305-243-1481
- E-mail: cxt582@med.miami.edu
-
Ledende efterforsker:
- Carmen Calfa, MD
-
Port Charlotte, Florida, Forenede Stater, 33980
- Aktiv, ikke rekrutterende
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Sarasota, Florida, Forenede Stater, 34236
- Aktiv, ikke rekrutterende
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Sarasota, Florida, Forenede Stater, 34239
- Aktiv, ikke rekrutterende
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
St. Petersburg, Florida, Forenede Stater, 33701
- Aktiv, ikke rekrutterende
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Tampa, Florida, Forenede Stater, 33607
- Aktiv, ikke rekrutterende
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Tavares, Florida, Forenede Stater, 32778
- Aktiv, ikke rekrutterende
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
The Villages, Florida, Forenede Stater, 32159
- Aktiv, ikke rekrutterende
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Trinity, Florida, Forenede Stater, 34655
- Aktiv, ikke rekrutterende
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Venice, Florida, Forenede Stater, 34285
- Aktiv, ikke rekrutterende
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Venice, Florida, Forenede Stater, 34292
- Aktiv, ikke rekrutterende
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Winter Park, Florida, Forenede Stater, 32789
- Aktiv, ikke rekrutterende
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30322
- Rekruttering
- Emory University Winship Cancer Institute
-
Ledende efterforsker:
- Olatunji Alese, MD
-
Kontakt:
- Krystal Bagley
- Telefonnummer: 404-778-8670
- E-mail: krystal.joi.bagley@emory.edu
-
Atlanta, Georgia, Forenede Stater, 30265
- Rekruttering
- Cancer Treatment Centers of America - Atlanta
-
Ledende efterforsker:
- Bamidele Adesunloye, MD
-
Kontakt:
- Elizabeth McKoy, RN, BSN
- Telefonnummer: 770-400-7177
- E-mail: emckoy@coh.org
-
Savannah, Georgia, Forenede Stater, 31405
- Rekruttering
- Summit Cancer Care
-
Ledende efterforsker:
- Mark Taylor, MD
-
Kontakt:
- Stephanie Smith, RN, MSN, OCN
- Telefonnummer: 9128195723
- E-mail: smiths1@sjchs.org
-
Savannah, Georgia, Forenede Stater, 31405
- Rekruttering
- Gynecologic Oncology and Surgical Specialists at the Lewis Cancer & Research Pavilion
-
Ledende efterforsker:
- Mark Taylor, MD
-
Kontakt:
- Stephanie Smith, RN, MSN, OCN
- Telefonnummer: 9128195723
- E-mail: smiths1@sjchs.org
-
Savannah, Georgia, Forenede Stater, 31405
- Rekruttering
- Lewis Cancer & Research Pavilion at the Melanoma, Skin Cancer & Sarcoma Institute
-
Ledende efterforsker:
- Mark Taylor, MD
-
Kontakt:
- Stephanie Smith, RN, MSN, OCN
- Telefonnummer: 19128195723
- E-mail: smiths1@sjchs.org
-
Savannah, Georgia, Forenede Stater, 31405
- Rekruttering
- Lewis Cancer & Research Pavilion
-
Kontakt:
- Stephanie Smith, RN, MSN, OCN
- Telefonnummer: 912-819-5723
- E-mail: smiths1@sjchs.org
-
Ledende efterforsker:
- Mark Taylor, MD
-
-
Hawaii
-
Honolulu, Hawaii, Forenede Stater, 96813
- Rekruttering
- The Queen's Medical Center - POB I
-
Ledende efterforsker:
- Jared Acoba, MD
-
Kontakt:
- Tim Kelleher
- Telefonnummer: 8086918582
- E-mail: tkelleher@queens.org
-
Honolulu, Hawaii, Forenede Stater, 96813
- Rekruttering
- The Queen's Medical Center - Punchbowl
-
Ledende efterforsker:
- Jared Acoba, MD
-
Kontakt:
- Tim Kelleher
- Telefonnummer: 808 691-8582
- E-mail: tkelleher@queens.org
-
Honolulu, Hawaii, Forenede Stater, 96817
- Rekruttering
- The Queen's Medical Center - Kuakini
-
Ledende efterforsker:
- Jared Acoba, MD
-
Kontakt:
- Tim Kelleher
- Telefonnummer: 8086918582
- E-mail: tkelleher@queens.org
-
‘Ewa Beach, Hawaii, Forenede Stater, 96706
- Rekruttering
- The Queen's Medical Center - West Oahu
-
Ledende efterforsker:
- Jared Acoba, MD
-
Kontakt:
- Tim Kelleher
- Telefonnummer: 8086918582
- E-mail: tkelleher@queens.org
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60099
- Rekruttering
- Cancer Treatment Centers of America-Chicago
-
Ledende efterforsker:
- Evan Pisick, MD
-
Kontakt:
- Office of Clinical Trials
- Telefonnummer: 847-731-1777
- E-mail: CHIResearch@coh.org
-
-
Indiana
-
Indianapolis, Indiana, Forenede Stater, 46250
- Rekruttering
- Community Health Network (The University of Texas MD Anderson Cancer Center)
-
Ledende efterforsker:
- Funda Meric-Bernstam, MD
-
Kontakt:
- Kshipra Sharma, MPH, MS
- Telefonnummer: 713-745-8431
- E-mail: Ksharma2@MDAnderson.org
-
-
Maine
-
Augusta, Maine, Forenede Stater, 04330
- Rekruttering
- Harold Alfond Center for Cancer Care
-
Kontakt:
- Sandra Neptune, BSN, RN
- Telefonnummer: 207-626-4811
- E-mail: sandra.neptune@mainegeneral.org
-
Ledende efterforsker:
- Lindsay Hathaway, MD
-
Augusta, Maine, Forenede Stater, 04330
- Rekruttering
- Jackson Laboratory - Maine Cancer Genomics Initiative
-
Kontakt:
- Petra Helbig, CCRP
- Telefonnummer: 207-664-4659
- E-mail: Petra.Helbig@jax.org
-
Ledende efterforsker:
- Jens Rueter, MD
-
Belfast, Maine, Forenede Stater, 04915
- Rekruttering
- Waldo County General Hospital
-
Ledende efterforsker:
- Roger Inhorn, MD
-
Kontakt:
- Jen - Dalton, MHA, BSN, RN
- Telefonnummer: 2072948291
- E-mail: JDalton@mmc.org
-
Biddeford, Maine, Forenede Stater, 04005
- Rekruttering
- SMHC Cancer Care and Blood Disorders -Biddeford
-
Ledende efterforsker:
- Roger Inhorn, MD
-
Kontakt:
- Jen - Dalton
- Telefonnummer: 2072948291
- E-mail: JDalton@mmc.org
-
Brewer, Maine, Forenede Stater, 04412
- Rekruttering
- Northern Light Cancer Care
-
Ledende efterforsker:
- Sarah Sinclair, MD
-
Kontakt:
- Carla Mancini, MHA, BSN, RN
- Telefonnummer: 207-973-5581
- E-mail: cmancini@northernlight.org
-
Brewer, Maine, Forenede Stater, 04412
- Rekruttering
- Raish Peavey Haskell Children's Cancer and Treatment Center
-
Ledende efterforsker:
- Sarah Sinclair, MD
-
Kontakt:
- Carla C Mancini, RN, BSN, OCN
- Telefonnummer: 2079735581
- E-mail: cmancini@northernlight.org
-
Brunswick, Maine, Forenede Stater, 04011
- Rekruttering
- MaineHealth Cancer Care -Brunswick
-
Ledende efterforsker:
- Roger Inhorn, MD
-
Kontakt:
- Jen - Dalton, MHA, BSN, RN
- Telefonnummer: 2072948291
- E-mail: JDalton@mmc.org
-
Kennebunk, Maine, Forenede Stater, 04043
- Rekruttering
- New England Cancer Specialist
-
Ledende efterforsker:
- Christian Thomas, MD
-
Kontakt:
- Patricia C Collins
- Telefonnummer: 2073033422
- E-mail: collip@newecs.org
-
Kittery, Maine, Forenede Stater, 03904
- Rekruttering
- York Hopsital Oncology & Infusion Care in Kittery
-
Ledende efterforsker:
- Marilyn McLaughlin, MD
-
Kontakt:
- Brenda i Kiberd, RN
- Telefonnummer: 2073616115
- E-mail: Brenda.Kiberd@yorkhospital.com
-
Norway, Maine, Forenede Stater, 04268
- Rekruttering
- Stephens Memorial Hospital
-
Ledende efterforsker:
- Roger Inhorn, MD
-
Kontakt:
- Jen - Dalton, MHA, BSN, RN
- Telefonnummer: 2072948291
- E-mail: JDalton@mmc.org
-
Rockport, Maine, Forenede Stater, 04856
- Rekruttering
- Penobscot Bay Medical Center
-
Ledende efterforsker:
- Roger Inhorn, MD
-
Kontakt:
- Jen - Dalton, MHA, BSN, RN
- Telefonnummer: 2072948291
- E-mail: JDalton@mmc.org
-
Sanford, Maine, Forenede Stater, 04073
- Rekruttering
- SMHC Cancer Care and Blood Disorders -Sandford
-
Ledende efterforsker:
- Roger Inhorn, MD
-
Kontakt:
- Jen - Dalton, MHA, BSN, RN
- Telefonnummer: 2072948291
- E-mail: JDalton@mmc.org
-
Scarborough, Maine, Forenede Stater, 04074
- Rekruttering
- Maine Children's Cancer Program
-
Ledende efterforsker:
- Roger Inhorn, MD
-
Kontakt:
- Jen - Dalton, MHA, BSN, RN
- Telefonnummer: 2072948291
- E-mail: JDalton@mmc.org
-
Scarborough, Maine, Forenede Stater, 04074
- Rekruttering
- Maine Medical Partner's Women's Health
-
Ledende efterforsker:
- Roger Inhorn, MD
-
Kontakt:
- Jen - Dalton, MHA, BSN, RN
- Telefonnummer: 2072948291
- E-mail: JDalton@mmc.org
-
Scarborough, Maine, Forenede Stater, 04074
- Rekruttering
- New England Cancer Specialist
-
Ledende efterforsker:
- Christian Thomas, MD
-
Kontakt:
- Patricia Collins, BA, CCRC
- Telefonnummer: 207-303-3422
- E-mail: collip@newecs.org
-
South Portland, Maine, Forenede Stater, 04106
- Rekruttering
- MaineHealth Cancer Care -South Portland
-
Kontakt:
- Jen Dalton, MHA, BSN, RN
- Telefonnummer: 207-294-8291
- E-mail: JDalton@mmc.org
-
Ledende efterforsker:
- Roger Inhorn, MD
-
Topsham, Maine, Forenede Stater, 04086
- Rekruttering
- New England Cancer Specialist
-
Ledende efterforsker:
- Christian Thomas, MD
-
Kontakt:
- Patricia C Collins, BA, CCRC
- Telefonnummer: 12073033422
- E-mail: collip@newecs.org
-
Wells, Maine, Forenede Stater, 04090
- Rekruttering
- York Hospital Oncology & Infusion Care in Wells
-
Ledende efterforsker:
- Marilyn McLaughlin, MD
-
Kontakt:
- Brenda Kiberd, RN
- Telefonnummer: 207-361-6115
- E-mail: Brenda.Kiberd@yorkhospital.com
-
York Village, Maine, Forenede Stater, 03909
- Rekruttering
- York Hospital Oncology & Infusion Care in York
-
Ledende efterforsker:
- Marilyn McLaughlin, MD
-
Kontakt:
- Brenda i Kiberd, RN
- Telefonnummer: 2073616115
- E-mail: Brenda.Kiberd@yorkhospital.com
-
-
Michigan
-
Ann Arbor, Michigan, Forenede Stater, 48109
- Aktiv, ikke rekrutterende
- University of Michigan
-
Ann Arbor, Michigan, Forenede Stater, 48106
- Rekruttering
- Trinity Health Ann Arbor Hospital
-
Ledende efterforsker:
- Elie Dib, MD
-
Kontakt:
- Telefonnummer: 7347123671
- E-mail: MCRCwebsitecontactform@trinity-health.org
-
Detroit, Michigan, Forenede Stater, 48236
- Rekruttering
- Henry Ford Health Saint John Hospital
-
Ledende efterforsker:
- Carrie Dul, MD
-
Kontakt:
- Telefonnummer: 7347123671
- E-mail: MCRCwebsitecontactform@trinity-health.org
-
Flint, Michigan, Forenede Stater, 48503
- Rekruttering
- Genesys Hurley Cancer Institute
-
Ledende efterforsker:
- Paul Adams, MD
-
Kontakt:
- Telefonnummer: 7347123671
- E-mail: MCRCwebsitecontactform@trinity-health.org
-
Grand Rapids, Michigan, Forenede Stater, 49503
- Rekruttering
- Cancer Research Consortium of West Michigan
-
Kontakt:
- Connie Szczepanek, RN
- Telefonnummer: 616-391-1230
- E-mail: crcwm-regulatory@crcwm.org
-
Ledende efterforsker:
- Kathleen J. Yost, MD
-
Lansing, Michigan, Forenede Stater, 48912
- Rekruttering
- University of Michigan Health - Sparrow Lansing
-
Ledende efterforsker:
- Gordan Srkalovic, MD
-
Kontakt:
- Telefonnummer: 7347123671
- E-mail: MCRCwebsitecontactform@trinity-health.org
-
Livonia, Michigan, Forenede Stater, 48154
- Rekruttering
- Trinity Health Livonia Hospital
-
Ledende efterforsker:
- Amit Mohindra, MD
-
Kontakt:
- Telefonnummer: 7347127251
- E-mail: MCRCwebsitecontactform@trinity-health.org
-
Pontiac, Michigan, Forenede Stater, 48341
- Rekruttering
- Trinity Health Oakland Hospital
-
Ledende efterforsker:
- Julie Goodman, MD
-
Kontakt:
- Telefonnummer: 7347123671
- E-mail: MCRCwebsitecontactform@trinity-health.org
-
Saginaw, Michigan, Forenede Stater, 48601
- Rekruttering
- MyMichigan Medical Center Saginaw
-
Ledende efterforsker:
- Nicholas Damico, MD
-
Kontakt:
- Telefonnummer: 7347123671
- E-mail: MCRCwebsitecontactform@trinity-health.org
-
Traverse City, Michigan, Forenede Stater, 48341
- Rekruttering
- Michigan Cancer Research Consortium
-
Ledende efterforsker:
- Philip Stella, MD
-
Kontakt:
- Beth LaVasseur, RN, MS
- Telefonnummer: 734-712-7251
- E-mail: Beth.LaVasseur@stjoeshealth.org
-
Kontakt:
- Telefonnummer: 877-590-5995
-
Warren, Michigan, Forenede Stater, 48093
- Rekruttering
- Henry Ford Health Warren Hospital
-
Ledende efterforsker:
- Carrie Dul, MD
-
Kontakt:
- Telefonnummer: 7347123671
- E-mail: MCRCwebsitecontactform@trinity-health.org
-
-
Nebraska
-
Omaha, Nebraska, Forenede Stater, 68198
- Rekruttering
- University of Nebraska Medical Center
-
Ledende efterforsker:
- Alissa Marr, MD
-
Kontakt:
- Micki Bethea, BS
- Telefonnummer: 402-559-8011
- E-mail: mbethea@unmc.edu
-
-
New Hampshire
-
Concord, New Hampshire, Forenede Stater, 03103
- Rekruttering
- NH Oncology - Hematology, PA
-
Kontakt:
- Ali Fleury
- Telefonnummer: 6033146888
- E-mail: A.Fleury@nhoh.com
-
Ledende efterforsker:
- Michael Buff, MD
-
Manchester, New Hampshire, Forenede Stater, 03103
- Rekruttering
- Solinsky Center for Cancer Care
-
Kontakt:
- Ali Fleury, BA, CCRP
- Telefonnummer: 603-314-6888
- E-mail: A.Fleury@nhoh.com
-
Ledende efterforsker:
- Michael Buff, MD
-
Portsmouth, New Hampshire, Forenede Stater, 03801
- Rekruttering
- New England Cancer Specialist
-
Ledende efterforsker:
- Christian Thomas, MD
-
Kontakt:
- Patricia C Collins, BA, CCRC
- Telefonnummer: 2073033422
- E-mail: collip@newecs.org
-
-
New Mexico
-
Albuquerque, New Mexico, Forenede Stater, 87110
- Rekruttering
- Presbyterian Kaseman Hospital
-
Ledende efterforsker:
- Bernard Tawfik, MD
-
Kontakt:
- Monique Robertson, RN
- Telefonnummer: (505)- 559-6100
- E-mail: mrobertso2@phs.org
-
Albuquerque, New Mexico, Forenede Stater, 87102
- Rekruttering
- Lovelace Medical Center - Saint Joseph Square
-
Ledende efterforsker:
- Bernard Tawfik, MD
-
Kontakt:
- Leslie Byatt
- Telefonnummer: (505) -925-0366
- E-mail: lpbyatt@salud.unm.edu
-
Albuquerque, New Mexico, Forenede Stater, 87131
- Rekruttering
- The University of New Mexico Comprehensive Cancer Center
-
Ledende efterforsker:
- Bernard Tawfik, MD
-
Kontakt:
- Sheri Westgate, RN-BSN, OCN
- Telefonnummer: (505) -925-0383
- E-mail: swestgate@salud.unm.edu
-
Las Cruces, New Mexico, Forenede Stater, 88011
- Rekruttering
- Memorial Medical Center
-
Ledende efterforsker:
- Bernard Tawfik, MD
-
Kontakt:
- Kim Hoffman, RN
- Telefonnummer: (575)- 556-6545
- E-mail: kim.hoffman@lpnt.net
-
Rio Rancho, New Mexico, Forenede Stater, 87124
- Rekruttering
- Presbyterian Rust Medical Center
-
Ledende efterforsker:
- Bernard Tawfik, MD
-
Kontakt:
- Andrea Yost
- Telefonnummer: (505) -253-7878
- E-mail: ayost3@phs.org
-
-
New York
-
Lake Success, New York, Forenede Stater, 11042
- Rekruttering
- Northwell Health Monter Cancer Center
-
Kontakt:
- Mary Agnes Templeton
- Telefonnummer: 516-734-8979
- E-mail: mtempleton@northwell.edu
-
Ledende efterforsker:
- Marina Frimer, MD
-
Mount Kisco, New York, Forenede Stater, 10549
- Rekruttering
- Northern Westchester Hospital
-
Ledende efterforsker:
- Marina Frimer, MD
-
Kontakt:
- Jemima Jacob, MPH
- Telefonnummer: 914-666-1366
- E-mail: jjacob22@northwell.edu
-
New Hyde Park, New York, Forenede Stater, 11040
- Rekruttering
- Cohen Children's Medical Center
-
Kontakt:
- Shreya Seepersaud
- Telefonnummer: 718-470-7146
- E-mail: sseepersaud2@northwell.edu
-
Ledende efterforsker:
- Marina Frimer, MD
-
New York, New York, Forenede Stater, 10065
- Rekruttering
- Manhattan Eye, Ear, and Throat Hospital
-
Ledende efterforsker:
- Marina Frimer, MD
-
Kontakt:
- Leila Nasr
- E-mail: lnasr@northwell.edu
-
New York, New York, Forenede Stater, 10305
- Rekruttering
- Staten Island University Hospital
-
Ledende efterforsker:
- Marina Frimer, MD
-
Kontakt:
- Sammi Ruan
- Telefonnummer: 718-226-1489
- E-mail: sruan2@northwell.edu
-
Kontakt:
- Melissa McCarthy
- Telefonnummer: 718-226-1805
- E-mail: mccarthy22@northwell.edu
-
Rego Park, New York, Forenede Stater, 11374
- Rekruttering
- Queens Cancer Center
-
Ledende efterforsker:
- Marina Frimer, MD
-
Kontakt:
- Harmandeep Kaur
- Telefonnummer: 718-412-0773
- E-mail: hkaur37@northwell.edu
-
Sleepy Hollow, New York, Forenede Stater, 10591
- Rekruttering
- Phelps Hospital
-
Ledende efterforsker:
- Marina Frimer, MD
-
Kontakt:
- Barbara Turner, RN
- Telefonnummer: 914-269-1949
- E-mail: Bturner1@northwell.edu
-
Kontakt:
- Shyrley Gomez
- E-mail: Sgomez21@northwell.edu
-
-
North Carolina
-
Chapel Hill, North Carolina, Forenede Stater, 27599
- Rekruttering
- Lineberger Comprehensive Cancer Center
-
Ledende efterforsker:
- Shetal Patel, MD
-
Kontakt:
- Emmie Cole
- Telefonnummer: 919-966-4432
- E-mail: emmie_cole@med.unc.edu
-
Charlotte, North Carolina, Forenede Stater, 28277
- Rekruttering
- Atrium Health's Levine Cancer Institute
-
Ledende efterforsker:
- Kathryn F. Mileham, MD, FACP
-
Kontakt:
- Jenna Gregory, MS, RN
- E-mail: Jenna.Gregory@atriumhealth.org
-
-
North Dakota
-
Bismarck, North Dakota, Forenede Stater, 58501
- Rekruttering
- Sanford Health- Bismarck
-
Kontakt:
- Peter Kurniali, MD
- Telefonnummer: 701-323-5741
- E-mail: peter.kurniali@sanfordhealth.org
-
Ledende efterforsker:
- Peter Kurniali, MD
-
Fargo, North Dakota, Forenede Stater, 58122
- Rekruttering
- Sanford Health- Fargo
-
Kontakt:
- Anu Gaba, MD
- Telefonnummer: 701-234-6161
- E-mail: anu.gaba@sanfordhealth.org
-
Ledende efterforsker:
- Anu Gaba, MD
-
-
Ohio
-
Cincinnati, Ohio, Forenede Stater, 45219
- Rekruttering
- University of Cincinnati Medical Center
-
Ledende efterforsker:
- Davendra Sohal, MD
-
Kontakt:
- Kayla Webb, MSN, RN
- Telefonnummer: 513-584-0599
- E-mail: webb2ka@ucmail.uc.edu
-
Kettering, Ohio, Forenede Stater, 45429
- Rekruttering
- Kettering Health
-
Kontakt:
- Allison Dymacek, BSN, RN
- Telefonnummer: 937-395-8367
- E-mail: allison.dymacek@ketteringhealth.org
-
Ledende efterforsker:
- Lex Leonhardt, DO
-
West Chester, Ohio, Forenede Stater, 45069
- Rekruttering
- West Chester Hospital
-
Ledende efterforsker:
- Trisha Wise-Draper, MD
-
Kontakt:
- Kayla Webb, MSN, RN
- Telefonnummer: 513-584-0599
- E-mail: webb2ka@ucmail.uc.edu
-
-
Oregon
-
Portland, Oregon, Forenede Stater, 97213
- Rekruttering
- Providence Health & Services
-
Ledende efterforsker:
- Evthokia Hobbs, MD
-
Kontakt:
- Isa Ngirailemesang
- Telefonnummer: 971-358-2056
- E-mail: Isa.Ngirailemesang@providence.org
-
-
Pennsylvania
-
Allentown, Pennsylvania, Forenede Stater, 18103
- Rekruttering
- Lehigh Valley Hospital - Cedar Crest
-
Kontakt:
- Telefonnummer: 734-712-3671
- E-mail: MCRCwebsitecontactform@trinity-health.org
-
Ledende efterforsker:
- Maged Khalil, MD
-
Bethlehem, Pennsylvania, Forenede Stater, 18017
- Rekruttering
- Lehigh Valley Hospital- Muhlenberg
-
Ledende efterforsker:
- Maged Khalil, MD
-
Kontakt:
- Telefonnummer: 7347127251
- E-mail: MCRCwebsitecontactform@trinity-health.org
-
East Stroudsburg, Pennsylvania, Forenede Stater, 18301
- Rekruttering
- Pocono Medical Center
-
Ledende efterforsker:
- Maged Khalil, MD
-
Kontakt:
- Telefonnummer: 7347127251
- E-mail: MCRCwebsitecontactform@trinity-health.org
-
Hazleton, Pennsylvania, Forenede Stater, 18201
- Rekruttering
- Lehigh Valley Hospital-Hazleton
-
Ledende efterforsker:
- Maged Khalil, MD
-
Kontakt:
- Telefonnummer: 7347127251
- E-mail: MCRCwebsitecontactform@trinity-health.org
-
Philadelphia, Pennsylvania, Forenede Stater, 19111
- Rekruttering
- Fox Chase Cancer Center
-
Ledende efterforsker:
- Margaret von Mehren, MD
-
Kontakt:
- Fathima S Sheriff
- Telefonnummer: 215-728-4094
- E-mail: fathima.sheriff@fccc.edu
-
-
South Carolina
-
Bluffton, South Carolina, Forenede Stater, 29910
- Rekruttering
- SC Cancer Specialists at St. Joseph's/Candler Bluffton
-
Ledende efterforsker:
- Mark Taylor, MD
-
Kontakt:
- Stephanie Smith, RN, MSN, OCN
- Telefonnummer: 19128195723
- E-mail: smiths1@sjchs.org
-
Bluffton, South Carolina, Forenede Stater, 29910
- Rekruttering
- St. Joseph's/Candler Smith
-
Ledende efterforsker:
- Mark Taylor, MD
-
Kontakt:
- Stephanie Smith, RN, MSN, OCN
- Telefonnummer: 19128195723
- E-mail: smiths1@sjchs.org
-
Bluffton, South Carolina, Forenede Stater, 29910
- Rekruttering
- Summit Cancer Care at St. Josph's/Candler Bluffton
-
Ledende efterforsker:
- Mark Taylor, MD
-
Kontakt:
- Stephanie Smith, RN, MSN, OCN
- Telefonnummer: 19128195723
- E-mail: smiths1@sjchs.org
-
Hilton Head Island, South Carolina, Forenede Stater, 29926
- Rekruttering
- South Carolina Cancer Specialists
-
Ledende efterforsker:
- Mark Taylor, MD
-
Kontakt:
- Stephanie Smith, RN, MSN, OCN
- Telefonnummer: 19128195723
- E-mail: smiths1@sjchs.org
-
-
South Dakota
-
Sioux Falls, South Dakota, Forenede Stater, 57104
- Rekruttering
- Sanford Cancer Center Oncology Clinic and Pharmacy
-
Ledende efterforsker:
- Steven Powell, MD
-
Kontakt:
- Steven Powell, MD
- Telefonnummer: 605-328-8000
- E-mail: steven.powell@sanfordhealth.org
-
-
Tennessee
-
Nashville, Tennessee, Forenede Stater, 37203
- Rekruttering
- Tennessee Oncology - Nashville / Sarah Cannon Research Institute
-
Kontakt:
- Ethan Trull
- Telefonnummer: 615-329-7274
- E-mail: Ethan.Trull@SarahCannon.com
-
Ledende efterforsker:
- Meredith McKean, MD, MPH
-
-
Texas
-
Houston, Texas, Forenede Stater, 77030
- Rekruttering
- The University of Texas MD Anderson Cancer Center
-
Ledende efterforsker:
- Funda Meric-Bernstam, MD
-
Kontakt:
- Kshipra Sharma, MPH, MS
- Telefonnummer: 713-745-8431
- E-mail: Ksharma2@MDAnderson.org
-
-
Utah
-
Cedar City, Utah, Forenede Stater, 84720
- Rekruttering
- Cedar City Hospital, SW Cancer Clinic, Sandra Maxwell Cancer Center
-
Ledende efterforsker:
- Ramya Thota, MD
-
Kontakt:
- Jake Kolu
- Telefonnummer: 435-705-1632
- E-mail: Jake.Kolu@imail.org
-
Ledende efterforsker:
- Derrick Haslem, MD
-
Salt Lake City, Utah, Forenede Stater, 84107
- Rekruttering
- Intermountain Healthcare
-
Kontakt:
- Tracy Taylor
- Telefonnummer: 801-507-3953
- E-mail: tracy.taylor@imail.org
-
Ledende efterforsker:
- Ramya Thota, M.D.
-
Ledende efterforsker:
- Derrick Haslem, M.D.
-
St. George, Utah, Forenede Stater, 84770
- Rekruttering
- Dixie Regional Medical Center-River Road Campus
-
Ledende efterforsker:
- Ramya Thota, MD
-
Kontakt:
- Jake Kolu
- Telefonnummer: 435-705-1632
- E-mail: Jake.Kolu@imail.org
-
Ledende efterforsker:
- Derrick Haslem, MD
-
-
Virginia
-
Fairfax, Virginia, Forenede Stater, 22042
- Rekruttering
- Inova Schar Cancer Institute
-
Ledende efterforsker:
- Timothy Cannon, MD
-
Kontakt:
- Roxana Comfort, CRC
- Telefonnummer: 571-472-0628
- E-mail: roxana.comfort@inova.org
-
-
Washington
-
Bonney Lake, Washington, Forenede Stater, 98391
- Rekruttering
- Northwest Medical Specialties
-
Kontakt:
- Jennifer Spokely
- Telefonnummer: 253-999-3701
- E-mail: research@southsoundcare.org
-
Ledende efterforsker:
- Frank Senecal, MD
-
Federal Way, Washington, Forenede Stater, 98003
- Rekruttering
- Northwest Medical Specialties
-
Kontakt:
- Jennifer Spokely
- Telefonnummer: 253-999-3701
- E-mail: research@southsoundcare.org
-
Ledende efterforsker:
- Frank Senecal, MD
-
Gig Harbor, Washington, Forenede Stater, 98332
- Rekruttering
- Northwest Medical Specialties
-
Kontakt:
- Jennifer Spokely
- Telefonnummer: 253-999-3701
- E-mail: research@southsoundcare.org
-
Ledende efterforsker:
- Frank Senecal, MD
-
Olympia, Washington, Forenede Stater, 98502
- Rekruttering
- Northwest Medical Specialties
-
Kontakt:
- Jennifer Spokely
- Telefonnummer: 253-999-3701
- E-mail: research@southsoundcare.org
-
Ledende efterforsker:
- Frank Senecal, MD
-
Puyallup, Washington, Forenede Stater, 98373
- Rekruttering
- Northwest Medical Specialties
-
Ledende efterforsker:
- Frank Senecal, MD
-
Kontakt:
- Jennifer Spokely
- Telefonnummer: 253-999-3701
- E-mail: reserch@southsoundcare.org
-
Seattle, Washington, Forenede Stater, 98104
- Rekruttering
- Swedish Cancer Institute
-
Ledende efterforsker:
- Philip Gold, MD
-
Kontakt:
- Sidney Ching
- Telefonnummer: 206-386-3142
- E-mail: sidney.ching@swedish.org
-
Tacoma, Washington, Forenede Stater, 98405
- Rekruttering
- Northwest Medical Specialties
-
Ledende efterforsker:
- Frank Senecal, MD
-
Kontakt:
- Jennifer Spokely
- Telefonnummer: 253-999-3701
- E-mail: reserch@southsoundcare.org
-
-
Wisconsin
-
Burlington, Wisconsin, Forenede Stater, 53105
- Rekruttering
- Aurora Cancer Care - Burlington
-
Ledende efterforsker:
- Antony Ruggeri, MD
-
Kontakt:
- Michelle Toutloff, RN, CCRP
- Telefonnummer: 9204567880
- E-mail: Michelle.Martin2@aah.org
-
Germantown, Wisconsin, Forenede Stater, 53022
- Rekruttering
- Aurora Health Care - Germantown Health Center
-
Ledende efterforsker:
- Antony Ruggeri, MD
-
Kontakt:
- Michelle Toutloff, RN, CCRP
- Telefonnummer: 9204567880
- E-mail: Michelle.Martin2@aah.org
-
Grafton, Wisconsin, Forenede Stater, 53024
- Rekruttering
- Aurora Cancer Care - Grafton
-
Ledende efterforsker:
- Antony Ruggeri, MD
-
Kontakt:
- Michelle Toutloff, RN, CCRP
- Telefonnummer: 9204567880
- E-mail: Michelle.Martin2@aah.org
-
Green Bay, Wisconsin, Forenede Stater, 54311
- Rekruttering
- Aurora BayCare Medical Center
-
Ledende efterforsker:
- Antony Ruggeri, MD
-
Kontakt:
- Michelle Toutloff, RN, CCRP
- Telefonnummer: 9204567880
- E-mail: Michelle.Martin2@aah.org
-
Kenosha, Wisconsin, Forenede Stater, 53142
- Rekruttering
- Aurora Cancer Care - Kenosha South
-
Ledende efterforsker:
- Antony Ruggeri, MD
-
Kontakt:
- Michelle Toutloff, RN, CCRP
- Telefonnummer: 9204567880
- E-mail: Michelle.Martin2@aah.org
-
Marinette, Wisconsin, Forenede Stater, 54143
- Rekruttering
- Aurora Bay Area Medical Center
-
Ledende efterforsker:
- Antony Ruggeri, MD
-
Kontakt:
- Michelle Toutloff, RN, CCRP
- Telefonnummer: 9204567880
- E-mail: Michelle.Martin2@aah.org
-
Milwaukee, Wisconsin, Forenede Stater, 53215
- Rekruttering
- Aurora St. Luke's Medical Center
-
Ledende efterforsker:
- Antony Ruggeri, MD
-
Kontakt:
- Michelle M Toutloff, RN, CCRP
- Telefonnummer: 9204567880
- E-mail: Michelle.Martin2@aah.org
-
Milwaukee, Wisconsin, Forenede Stater, 53209
- Rekruttering
- Aurora Cancer Care Milwaukee
-
Ledende efterforsker:
- Antony Ruggeri, MD
-
Kontakt:
- Michelle M Toutloff, RN, CCRP
- Telefonnummer: 9204567880
- E-mail: Michelle.Martin2@aah.org
-
Milwaukee, Wisconsin, Forenede Stater, 53223
- Rekruttering
- Aurora Sinai Medical Center
-
Ledende efterforsker:
- Antony Ruggeri, MD
-
Kontakt:
- Michelle Toutloff, RN, CCRP
- Telefonnummer: 9204567880
- E-mail: Michelle.Martin2@aah.org
-
Milwaukee, Wisconsin, Forenede Stater, 53227
- Rekruttering
- Aurora West Allis Medical Center
-
Ledende efterforsker:
- Antony Ruggeri, MD
-
Kontakt:
- Michelle Toutloff, RN, CCRP
- Telefonnummer: 9204567880
- E-mail: Michelle.Martin2@aah.org
-
Oshkosh, Wisconsin, Forenede Stater, 54904
- Rekruttering
- Vince Lombardi Cancer Clinic - Oshkosh
-
Ledende efterforsker:
- Antony Ruggeri, MD
-
Kontakt:
- Michelle Toutloff, RN, CCRP
- Telefonnummer: 9204567880
- E-mail: Michelle.Martin2@aah.org
-
Racine, Wisconsin, Forenede Stater, 53406
- Rekruttering
- Aurora Cancer Care - Racine
-
Ledende efterforsker:
- Antony Ruggeri, MD
-
Kontakt:
- Michelle Toutloff, RN, CCRP
- Telefonnummer: 9204567880
- E-mail: Michelle.Martin2@aah.org
-
Sheboygan, Wisconsin, Forenede Stater, 53081
- Rekruttering
- Vince Lombardi Cancer Center
-
Ledende efterforsker:
- Antony Ruggeri, MD
-
Kontakt:
- Michelle Toutloff, RN, CCRP
- Telefonnummer: 9204567880
- E-mail: Michelle.Martin2@aah.org
-
Summit, Wisconsin, Forenede Stater, 53066
- Rekruttering
- Aurora Medical Center in Summit
-
Ledende efterforsker:
- Antony Ruggeri, MD
-
Kontakt:
- Michelle Toutloff, RN, CCRP
- Telefonnummer: 9204567880
- E-mail: Michelle.Martin2@aah.org
-
Two Rivers, Wisconsin, Forenede Stater, 54241
- Rekruttering
- Vince Lombardi Cancer Clinic - Two Rivers
-
Ledende efterforsker:
- Antony Ruggeri, MD
-
Kontakt:
- Michelle Toutloff, RN, CCRP
- Telefonnummer: 9204567880
- E-mail: Michelle.Martin2@aah.org
-
Wauwatosa, Wisconsin, Forenede Stater, 53226
- Rekruttering
- Aurora Cancer Care - Milwaukee West
-
Ledende efterforsker:
- Antony Ruggeri, MD
-
Kontakt:
- Michelle Toutloff, RN, CCRP
- Telefonnummer: 920-456-7880
- E-mail: Michelle.Martin2@aah.org
-
-
-
-
Puerto Rico
-
Cayey, Puerto Rico, Puerto Rico, 00737
- Rekruttering
- PanOncology Trials
-
Kontakt:
- Natalia Ortiz
- Telefonnummer: 787-407-3333
- E-mail: natalia.ortiz@panoncologytrials.com
-
Ledende efterforsker:
- Maria Cruz Correa, MD
-
Dorado, Puerto Rico, Puerto Rico, 00646
- Rekruttering
- PanOncology Trials
-
Kontakt:
- Natalia Ortiz
- Telefonnummer: 787-407-3333
- E-mail: natalia.ortiz@panoncologytrials.com
-
Ledende efterforsker:
- Maria Cruz Correa, MD
-
Manati, Puerto Rico, Puerto Rico, 00674
- Rekruttering
- PanOncology Trials
-
Kontakt:
- Natalia Ortiz
- Telefonnummer: 787-407-3333
- E-mail: natalia.ortiz@panoncologytrials.com
-
Ledende efterforsker:
- Maria Crus Correa, MD
-
Mayagüez, Puerto Rico, Puerto Rico, 00680
- Rekruttering
- PanOncology Trials
-
Kontakt:
- Natalia Ortiz
- Telefonnummer: 787-407-3333
- E-mail: natalia.ortiz@panoncologytrials.com
-
Ledende efterforsker:
- Maria Cruz Correa, MD
-
Ponce, Puerto Rico, Puerto Rico, 00730
- Rekruttering
- PanOncology Trials
-
Kontakt:
- Natalia Ortiz
- Telefonnummer: 787-407-3333
- E-mail: natalia.ortiz@panoncologytrials.com
-
Ledende efterforsker:
- Maria Cruz Correa, MD
-
San Juan, Puerto Rico, Puerto Rico, 00909
- Rekruttering
- PanOncology Trials
-
Kontakt:
- Natalia Ortiz
- Telefonnummer: 787-407-3333
- E-mail: natalia.ortiz@panoncologytrials.com
-
Ledende efterforsker:
- Maria Cruz Correa, MD
-
San Juan, Puerto Rico, Puerto Rico, 00935
- Rekruttering
- PanOncology Trials
-
Kontakt:
- Natalia Ortiz
- Telefonnummer: 787-407-3333
- E-mail: natalia.ortiz@panoncologytrials.com
-
Ledende efterforsker:
- Maria Cruz Correa, MD
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
-
12 years of age or older (*Restrictions apply. Not all therapies are available for patients <18)
-
Histologically-proven locally advanced or metastatic solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma who is no longer benefiting from standard anti-cancer treatment or for whom, in the opinion of the treating physician, no such treatment is available or indicated (except under the circumstance in which the TAPUR arm is designed to provide additional evidence to support an existing FDA indication).
-
Performance status 0-2 (Per Eastern Cooperative Oncology Group (ECOG) criteria)
-
Patients must have acceptable organ function as defined below. However, as noted above, drug-specific inclusion/exclusion criteria specified in the protocol appendix for each agent will take precedence for this and all inclusion criteria:
- Absolute neutrophil count ≥ 1500 µl
- Hemoglobin ≥ 9.0 g/dl
- Platelets ≥ 75,000/µl
- Total bilirubin < 2.0 mg/ dl, except in patients with Gilbert's Syndrome
- Aspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT) serum glutamic-pyruvic transaminase (SGPT) < 2.5 x institutional upper limit of normal (ULN) (or < 5 x ULN in patients with known hepatic metastases)
- Serum creatinine ≤ 1.5 × ULN or calculated or measured creatinine clearance ≥ 50 mL/min/1.73 m2
-
Patients must have disease that can be objectively measured by physical, laboratory or radiographic exam (per RECIST v1.1 for solid tumor, Lugano criteria for non-Hodgkin lymphoma or International Myeloma Working Group criteria for multiple myeloma).
-
Results must be available from a genomic test or immunohistochemistry (IHC) test for protein expression performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified and College of American Pathologists (CAP)-accredited or New York State accredited (for labs offering services to residents of NY) laboratory. Labs that have registered the test with the NIH Genetic Testing Registry or that provide a report that has been designated as optimized for TAPUR participation are preferred, but not required. The genomic or IHC test used to qualify a patient for participation in TAPUR may have been performed on any specimen of the patient's tumor obtained at any point during the patient's care at the discretion of the patient's treating physician. Genomic assays performed on cell-free DNA in plasma ("liquid biopsies") will also be acceptable if the genomic analysis is performed in a laboratory that meets the criteria described above.
-
Ability to understand and the willingness to sign a written informed consent/assent document.
-
Have a tumor genomic profile for which single agent treatment with one of the FDA approved targeted anti-cancer drugs included in this study has potential clinical benefit based on the criteria described in protocol.
-
For orally administered drugs, the patient must be able to swallow and tolerate oral medication and must have no known malabsorption syndrome.
-
Because of the risks of drug treatment to the developing fetus, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation, and for four months following completion of study therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study or if she is the partner of a male participant in this study and becomes pregnant while he is participating in this study, she should inform her or her partner's treating physician immediately as well as her obstetrician. Female study patients who become pregnant must immediately discontinue treatment with any study therapy. Male patients should avoid impregnating a female partner. Male study patients, even if surgically sterilized, (i.e. post-vasectomy) must agree to one of the following: practice effective barrier contraception during the entire study treatment period and for a specified amount of time the last dose of study treatment, or completely abstain from sexual intercourse.
Note: TAPUR does not explicitly exclude any type of solid tumor, but the patient must have measurable and evaluable disease per RECIST v1.1.
Exclusion Criteria:
- Patients whose disease is not measurable or cannot be assessed by radiographic imaging or physical examination (e.g., elevated serum tumor marker only) are not eligible
- Patients with primary brain tumors or new, untreated or progressive leptomeningeal metastases are excluded
- Patients with previously treated brain metastases or previously treated leptomeningeal disease are eligible, provided that the patient has not experienced a seizure or had a clinically significant change in neurological status within the 1 months prior to registration. All patients with previously treated brain metastases must be clinically stable for at least 1 month after completion of treatment and off steroid treatment for one month prior to study enrollment.
- Patients with known progressive brain metastases are eligible but additional eligibility criteria apply.
Note: there are additional exclusion criteria that may apply
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Andet: Group 5 (CSF1R,PDGFR,VEGFR)
Participants receive sunitinib - dosage, frequency and duration per label; acceptable genomic matches include CSF1R, PDGFR, VEGFR1/2/3, KIT, FLT-3, RET, FGFR1/2/3, VHL amplifications or mutations |
drug
Andre navne:
|
|
Andet: Group 8 (ERBB2)
Participants receive trastuzumab and pertuzumab - dosage, frequency and duration per label; acceptable genomic matches include ERBB2 amplification or overexpression, and specific ERBB2 mutations |
drug
Andre navne:
|
|
Andet: Group 9 (BRAF V600E/D/K/R)
Participants receive vemurafenib and cobimetinib - dosage, frequency and duration per label; acceptable genomic matches include BRAF V600E/D/K/R mutations |
drug
Andre navne:
|
|
Andet: Group 14 (BRCA1/2; ATM)
Participants receive olaparib - dosage, frequency and duration per label; acceptable genomic matches include germline or somatic BRCA1/2 inactivating mutations; ATM mutations or deletions |
drug
Andre navne:
|
|
Andet: Group 16 (MSI-H, high mutational load and others)
Participants receive nivolumab and ipilimumab - dosage, frequency and duration per label; acceptable genomic matches include MSI high status, high tumor mutational burden, MLH1, MSH2/6, PMS2, EPCAM mutations, specific POLE or POLD1 mutations, BRCA1/2, ATM, MSH3, PMS1, MLH3, EXO1, RFC1/2/3/4/5, PCNA, RPA1/2/3/4, and SSBP1 loss of function mutations |
drug
Andre navne:
|
|
Andet: Group 17 (CDKN2A, CDK4, CDK6)
Participants receive abemaciclib - dosage, frequency and duration per label; acceptable genomic matches include CDKN2A loss or mutation, CDK4, CDK6 amplifications, CDKN2B loss or mutation |
drug
Andre navne:
|
|
Andet: Group 19 (BRCA1/2, PALB2)
Participants receive talazoparib - dosage, frequency and duration per label; acceptable genomic matches include germline or somatic BRCA1/2 and PALB2 mutations |
drug
Andre navne:
|
|
Andet: Group 21 (BRCA1/2, PALB2, ATM, and others)
Participants receive atezolizumab plus talazoparib - dosage, frequency and duration per label; acceptable genomic matches include germline or somatic mutations in BRCA1/2, PALB2, ATM, ATR, CHEK2, FANCA, RAD51C, NBN, MLH1, MRE11A, CDK12; positive genomic instability score reported on the Myriad MyChoice CDx test; or Genomic Loss of Heterozygosity (LOH) Score above threshold as reported on a FoundationOne CDx test or another qualifying test for TAPUR with MTB approval |
drug
Andre navne:
|
|
Andet: Group 24 (ERBB2)
Participants receive tucatinib plus trastuzumab SC - dosage, frequency and duration per label; acceptable genomic matches include ERBB2 amplification or overexpression, and specific ERBB2 mutations |
drug
Andre navne:
|
|
Andet: Group 25
Participants receive futibatinib- dosage, frequency and duration per label; acceptable genomic matches include FGFR 1,2,3,4 fusion (or other rearrangement) or mutation |
drug
Andre navne:
|
|
Andet: Group 26 (BRAF V600 E mutation )
Participants receive Dabrafenib plus Trametinib - dosage, frequency and duration per label; acceptable genomic matches include BRAF V600 E mutation . |
Drug
Andre navne:
|
|
Andet: Group 27 (ERBB2 amplification, ERBB2 (HER2) IHC2+ or IHC3+ overexpression)
Participants receive Fam-trastuzumab deruxtecan-nxki (ENHERTU®) - dosage, frequency and duration per label; acceptable genomic matches include ERBB2 amplification, For NSCLC Only-ERBB2 (HER2) IHC2+ or IHC3+ overexpression without ERBB2 amplification) |
Drug
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Objective Response Rate defined as % of participants in a cohort with complete or partial response or with stable disease according to standard response criteria
Tidsramme: Assessed at 16 weeks of treatment
|
Each cohort includes participants with the same tumor type, genomic variant and study drug. For solid tumors, the Response Evaluation Criteria for Solid Tumors (RECIST) criteria will be used, for non-Hodgkin Lymphoma, the Lugano Criteria will be used, and for multiple myeloma, the International Uniform Response Criteria for Multiple Myeloma will be used. |
Assessed at 16 weeks of treatment
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Overall survival (OS)
Tidsramme: Duration of survival from registration on study until death from any cause, assessed throughout end of study, up to 3 years
|
OS will be estimated using the Kaplan-Meier method |
Duration of survival from registration on study until death from any cause, assessed throughout end of study, up to 3 years
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Publikationer og nyttige links
Generelle publikationer
- Alva AS, Mangat PK, Garrett-Mayer E, Halabi S, Hansra D, Calfa CJ, Khalil MF, Ahn ER, Cannon TL, Crilley P, Fisher JG, Haslem DS, Shrestha S, Antonelli KR, Butler NL, Warren SL, Rygiel AL, Ranasinghe S, Bruinooge SS, Schilsky RL. Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. J Clin Oncol. 2021 Aug 1;39(22):2443-2451. doi: 10.1200/JCO.20.02923. Epub 2021 Apr 12.
- Fisher JG, Tait D, Garrett-Mayer E, Halabi S, Mangat PK, Schink JC, Alvarez RH, Veljovich D, Cannon TL, Crilley PA, Pollock T, Calfa CJ, Al Baghdadi T, Thota R, Fleming N, Cotta JA, Rygiel AL, Warren SL, Schilsky RL. Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Target Oncol. 2020 Dec;15(6):733-741. doi: 10.1007/s11523-020-00753-7.
- Al Baghdadi T, Garrett-Mayer E, Halabi S, Mangat PK, Rich P, Ahn ER, Chai S, Rygiel AL, Osayameh O, Antonelli KR, Islam S, Bruinooge SS, Schilsky RL. Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Target Oncol. 2020 Dec;15(6):743-750. doi: 10.1007/s11523-020-00752-8.
- Gupta R, Meric-Bernstam F, Rothe M, Garrett-Mayer E, Mangat PK, D'Andre S, Ahn ER, O'Lone R, Halabi S, Grantham GN, Schilsky RL. Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2/3 Mutations: Results From the TAPUR Study. JCO Precis Oncol. 2022 Oct;6:e2200306. doi: 10.1200/PO.22.00306.
- Mangat PK, Kirkwood MK, Hinshaw DC, Garrett-Mayer E, Schilsky RL. Prevalence of targetable genomic alterations among a diverse population participating in the ASCO TAPUR Study. NPJ Precis Oncol. 2025 Jul 3;9(1):222. doi: 10.1038/s41698-025-00962-1.
- Worden FP, Pisick E, Rothe M, Mangat PK, Garrett-Mayer E, Khalil MF, Carrizosa DR, Bauman JR, Leidner RS, Duvivier HL, Fu S, Park MS, Yost KJ, Calfa CJ, Marr AS, Balmanoukian AS, Behl D, Cannon TL, Nabell L, Powell SF, Thota R, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Palbociclib in Patients With Head and Neck Cancer and Other Tumors With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2024 Oct;8:e2400477. doi: 10.1200/PO-24-00477. Epub 2024 Oct 16.
- Schuetze S, Rothe M, Mangat PK, Garrett-Mayer E, Meric-Bernstam F, Calfa CJ, Farrington LC, Livingston MB, Wentzel K, Behl D, Kier Y, Marr AS, von Mehren M, Press JZ, Thota R, Grantham GN, Gregory A, Hinshaw DC, Halabi S, Schilsky RL. Palbociclib in Patients With Soft Tissue Sarcoma With CDK4 Amplifications: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2024 Jul;8:e2400219. doi: 10.1200/PO.24.00219.
- Srkalovic G, Rothe M, Mangat PK, Garrett-Mayer E, Ahn ER, Brouse G, Chan J, Mehmi I, Khalil M, Duvivier HL, Gaba A, Leuva H, Thota R, Yost KJ, Grantham GN, Gregory A, Hinshaw DC, Halabi S, Schilsky RL. Talazoparib in Patients With Solid Tumors With BRCA1/2 Mutation: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2024 Jun;8:e2400026. doi: 10.1200/PO.24.00026.
- Cannon TL, Rothe M, Mangat PK, Garrett-Mayer E, Chiu VK, Hwang J, Vijayvergia N, Alese OB, Dib EG, Duvivier HL, Klute KA, Sahai V, Ahn ER, Bedano P, Behl D, Sinclair S, Thota R, Urba WJ, Yang ES, Grantham GN, Hinshaw DC, Gregory A, Halabi S, Schilsky RL. Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With ERBB2/3 Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. J Clin Oncol. 2024 Sep 20;42(27):3228-3237. doi: 10.1200/JCO.23.02078. Epub 2024 May 15.
- Perez JK, Kleber J, Rothe M, Mangat P, Garrett-Mayer E, Schilsky RL. Concordance in Molecular Tumor Board Case Reviews in the ASCO TAPUR Study. JCO Precis Oncol. 2024 Mar;8:e2300615. doi: 10.1200/PO.23.00615.
- Calfa CJ, Rothe M, Mangat PK, Garrett-Mayer E, Ahn ER, Burness ML, Gogineni K, Rohatgi N, Al Baghdadi T, Conlin A, Gaba A, Hamid O, Krishnamurthy J, Gavini NJ, Gold PJ, Rodon J, Rueter J, Thota R, Grantham GN, Hinshaw DC, Gregory A, Halabi S, Schilsky RL. Sunitinib in Patients With Breast Cancer With FGFR1 or FGFR2 Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2024 Feb;8:e2300513. doi: 10.1200/PO.23.00513.
- Meric-Bernstam F, Rothe M, Mangat PK, Garrett-Mayer E, Gutierrez R, Ahn ER, Cannon TL, Powell S, Krauss JC, Reynolds CM, von Mehren M, Behl D, Calfa CJ, Duvivier HL, Kaplan HG, Livingston MB, Sharma MR, Urba WJ, Grantham GN, Hinshaw DC, Gregory A, Halabi S, Schilsky RL. Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2023 Sep;7:e2300385. doi: 10.1200/PO.23.00385.
- Rohatgi N, Rothe M, Mangat PK, Garrett-Mayer E, Meric-Bernstam F, Pisick E, Alese OB, Reynolds CM, Thota R, Vaccaro GM, von Mehren M, Arend RC, Chiu VK, Duvivier HL, Gold PJ, Hack K, Marr AS, Winer A, Grantham GN, Hinshaw DC, Gregory A, Halabi S, Schilsky RL. Nivolumab Plus Ipilimumab in Patients With Solid Tumors With ATM Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2023 Sep;7:e2300279. doi: 10.1200/PO.23.00279.
- Duvivier HL, Rothe M, Mangat PK, Garrett-Mayer E, Ahn ER, Al Baghdadi T, Alva AS, Dublis SA, Cannon TL, Calfa CJ, Li R, Behl D, Chiu VK, Gold PJ, Marr AS, Mileham KF, Powell SF, Rodon J, Thota R, Grantham GN, Gregory A, Hinshaw DC, Halabi S, Schilsky RL. Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study. J Clin Oncol. 2023 Nov 20;41(33):5140-5150. doi: 10.1200/JCO.23.00702. Epub 2023 Aug 10.
- Mangat PK, Garrett-Mayer E, Perez JK, Schilsky RL. The Targeted Agent and Profiling Utilization Registry Study: A pragmatic clinical trial. Clin Trials. 2023 Dec;20(6):699-707. doi: 10.1177/17407745231182013. Epub 2023 Jul 25.
- Ganti AK, Rothe M, Mangat PK, Garrett-Mayer E, Dib EG, Duvivier HL, Ahn ER, Behl D, Borghaei H, Balmanoukian AS, Gaba A, Li R, Osei-Boateng K, Thota R, Grantham GN, Gregory A, Halabi S, Schilsky RL. Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2023 Jun;7:e2300041. doi: 10.1200/PO.23.00041.
- Ahn ER, Rothe M, Mangat PK, Garrett-Mayer E, Ali-Ahmad HM, Chan J, Maitland ML, Patel SR, Reese Z, Balmanoukian AS, Drescher CW, Li R, Tsimberidou AM, Leath CA 3rd, O'Lone R, Grantham GN, Halabi S, Schilsky RL. Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With ERBB2/3 Amplification, Overexpression, or Mutation: Results From the TAPUR Study. JCO Precis Oncol. 2023 Apr;7:e2200609. doi: 10.1200/PO.22.00609.
- Yang ES, Halabi S, Rothe M, Garrett-Mayer E, Mangat PK, Pisick E, Dib E, Burgess EF, Zakem M, Rohatgi N, Bilen MA, O'Lone R, Grantham GN, Schilsky RL. Olaparib in Patients With Metastatic Prostate Cancer With BRCA1/2 Mutation: Results From the TAPUR Study. JCO Precis Oncol. 2023 Feb;7:e2200505. doi: 10.1200/PO.22.00505.
- Carrizosa DR, Rothe M, Mangat PK, Garrett-Mayer E, Behl D, Adesunloye B, Pisick E, Beekman KW, Dotan E, Akce M, Alese OB, Sahai V, Klute KA, Aragon-Ching JB, Cooper KA, Thota R, Meric-Bernstam F, Hosein PJ, Maestas EC, Moyers JT, Powell S, Zhao S, Hobbs E, Rueter J, Sohal DPS, Taylor MA, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Olaparib in Patients With Solid Tumors With ATM Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2026 Jan;10:e2500716. doi: 10.1200/PO-25-00716. Epub 2026 Jan 15.
- Al Baghdadi T, Rothe M, Mangat PK, Garrett-Mayer E, Crysler OV, Mileham KF, Farrington LC, Adesunloye B, Dublis SA, Astsaturov I, Calfa CJ, Bleeker J, Khalil M, Thota R, Cannon TL, Alese OB, Gold PJ, Hafez N, Baron AD, Meric-Bernstam F, Hobbs E, Marr AS, Rueter J, Tawfik B, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Olaparib in Patients With Solid Tumors With BRCA1/2 Alterations: Results From The Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2025 Oct;9:e2500649. doi: 10.1200/PO-25-00649. Epub 2025 Oct 16.
- Cobain EF, Rothe M, Garrett-Mayer E, Cannon TL, Chan JK, Mileham KF, Adesunloye B, Calfa CJ, Alese OB, Butler KY, Dib EG, Pisick E, Bell M, Klute KA, Mehmi I, Meric-Bernstam F, Mangat PK, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Nivolumab Plus Ipilimumab in Patients With Solid Tumors With High Tumor Mutation Burden: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2026 Apr;10(4):e2501205. doi: 10.1200/PO-25-01205. Epub 2026 Apr 30.
- Pisick E, Rothe M, Garrett-Mayer E, Srkalovic G, Chan JK, Calfa CJ, Leath CA 3rd, Marr AS, Gold PJ, Crane EK, Moyers JT, Yost Butler K, Gaba A, Thota R, Harnden KK, Alese OB, Jain A, Rueter J, Gill S, George TJ, Frimer M, Kayali F, Mangat PK, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Temsirolimus in Patients With Solid Tumors With PIK3CA Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2026 Apr;10(4):e2500985. doi: 10.1200/PO-25-00985. Epub 2026 Apr 22.
- Veljovich DS, Rothe M, Garrett-Mayer E, Ali-Ahmad HM, Naumann RW, Siedel J, Chan JK, Gregory A, Pisick E, Adesunloye B, Arend RC, Bell M, Frimer M, Tawfik B, Thota R, Tsimberidou AM, Mangat PK, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Palbociclib in Patients With Ovarian Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2026 Jul;10(7):e2600456. doi: 10.1200/PO-26-00456. Epub 2026 Jul 15.
- Diamond-Rossi SA, Rothe M, Garrett-Mayer E, Pisick E, Bleeker J, Ganti AK, Meric-Bernstam F, Moyers JT, Nair SG, Kadakia KC, Rohatgi N, Sahai V, Vijayvergia N, Gold PJ, Sharma MR, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Cobimetinib + Vemurafenib in Patients With BRAF V600E-Mutant Papillary Thyroid and Biliary Tract Cancers: Results From the TAPUR Study. JCO Precis Oncol. 2026 Oct;10(10):e2600703. doi: 10.1200/PO-26-00703. Epub 2026 Oct 16.
- Srkalovic G, Rothe M, Garrett-Mayer E, Mileham KF, Adesunloye B, Pisick E, Leath CA 3rd, Colocci N, Chen MD, Meric-Bernstam F, Marr AS, Alese OB, Powell S, Rueter J, Benyounes A, Pontious C, Lewis MA, Thomas GW, Kier Y, Calfa CJ, von Mehren M, Acoba JD, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Sunitinib in Patients With Various Solid Tumors With FGFR1/2 Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2026 Oct;10(10):e2600454. doi: 10.1200/PO-26-00454. Epub 2026 Oct 7.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Anslået)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Karsygdomme
- Hjerte-kar-sygdomme
- Sygdomme i immunsystemet
- Neoplasmer efter histologisk type
- Hæmatologiske sygdomme
- Lymfesygdomme
- Lymfoproliferative lidelser
- Immunproliferative lidelser
- Lymfom
- Neoplasmer, Plasmacelle
- Hæmostatiske lidelser
- Paraproteinæmier
- Blodproteinforstyrrelser
- Hæmoragiske lidelser
- Hemiske og lymfatiske sygdomme
- Neoplasmer
- Myelomatose
- Lymfom, Non-Hodgkin
- Aminosyrer, peptider og proteiner
- Proteiner
- Svovlforbindelser
- Organiske kemikalier
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Heterocykliske forbindelser, 2-ring
- Heterocykliske forbindelser, smeltet ring
- Azoler
- Amider
- Indoler
- Antistoffer, monoklonal, humaniseret
- Antistoffer, monoklonal
- Antistoffer
- Immunoglobuliner
- Immunoproteiner
- Blodproteiner
- Serum globuliner
- Globuliner
- Pyrroles
- Sulfonamider
- Sulfoner
- Trastuzumab
- Sunitinib
- Nivolumab
- Ipilimumab
- Vemurafenib
- Abemaciclib
- Pertuzumab
- dabrafenib
- Trametinib
- atezolizumab
- Olaparib
- Talazoparib
- Cobimetinib
- Tucatinib
- futibatinib
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- Pro00014171
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .